See more : TianYu Eco-Environment Co., Ltd. (603717.SS) Income Statement Analysis – Financial Results
Complete financial analysis of BrainsWay Ltd. (BWAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BrainsWay Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Tomoe Engineering Co., Ltd. (6309.T) Income Statement Analysis – Financial Results
- The Lion Electric Company (LEV.TO) Income Statement Analysis – Financial Results
- Sparinvest Mix Lav Risiko KL (SPIMLRKLA.CO) Income Statement Analysis – Financial Results
- KTIS Corporation (058860.KS) Income Statement Analysis – Financial Results
- Taisun Int’l (Holding) Corporation (8480.TW) Income Statement Analysis – Financial Results
BrainsWay Ltd. (BWAY)
About BrainsWay Ltd.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.79M | 27.18M | 29.66M | 22.06M | 23.10M | 16.40M | 11.15M | 11.52M | 6.80M | 3.38M | 1.19M | 364.25K |
| Cost of Revenue | 8.31M | 7.13M | 6.60M | 5.06M | 5.13M | 3.59M | 2.60M | 2.43M | 1.47M | 656.00K | 199.00K | 46.07K |
| Gross Profit | 23.48M | 20.05M | 23.06M | 17.00M | 17.97M | 12.81M | 8.55M | 9.10M | 5.33M | 2.72M | 990.00K | 318.18K |
| Gross Profit Ratio | 73.86% | 73.77% | 77.75% | 77.07% | 77.80% | 78.11% | 76.72% | 78.94% | 78.44% | 80.59% | 83.26% | 87.35% |
| Research & Development | 6.67M | 7.68M | 6.39M | 5.82M | 7.88M | 6.16M | 5.34M | 3.79M | 4.10M | 6.44M | 3.69M | 5.97M |
| General & Administrative | 5.32M | 6.85M | 5.78M | 4.72M | 4.39M | 8.23M | 7.47M | 5.74M | 3.61M | 2.34M | 1.43M | 1.31M |
| Selling & Marketing | 16.46M | 18.20M | 15.88M | 11.28M | 13.27M | 3.11M | 1.83M | 1.21M | 1.93M | 1.21M | 633.00K | 140.34K |
| SG&A | 21.64M | 25.05M | 21.66M | 16.01M | 17.66M | 11.34M | 9.30M | 6.95M | 5.54M | 3.55M | 2.06M | 1.45M |
| Other Expenses | 133.00K | 0.00 | 0.00 | 0.00 | 916.00K | 427.00K | 523.00K | 426.00K | 200.00K | 11.00K | -504.00K | 0.00 |
| Operating Expenses | 28.44M | 32.73M | 28.06M | 21.83M | 26.45M | 17.92M | 15.16M | 11.17M | 9.84M | 10.00M | 5.26M | 5.95M |
| Cost & Expenses | 36.74M | 39.86M | 34.66M | 26.89M | 31.58M | 21.51M | 17.76M | 13.59M | 11.31M | 10.66M | 5.46M | 5.99M |
| Interest Income | 2.17M | 1.11M | 225.00K | 61.00K | 175.00K | 44.00K | 22.00K | 12.00K | 18.00K | 93.00K | 304.00K | 288.19K |
| Interest Expense | 48.00K | 46.00K | 1.42M | 319.00K | 398.00K | 354.00K | 360.00K | 404.00K | 98.00K | 525.00K | 283.00K | 0.00 |
| Depreciation & Amortization | 1.34M | 1.53M | 1.69M | 1.62M | 2.80M | 1.23M | 1.07M | 649.00K | 611.00K | 336.00K | 206.00K | 109.28K |
| EBITDA | -2.56M | -11.45M | -4.67M | -3.46M | -6.58M | -4.40M | -5.56M | -1.34M | -3.38M | -5.68M | -4.06M | -5.57M |
| EBITDA Ratio | -8.06% | -41.02% | -11.17% | -21.89% | -28.50% | -26.85% | -49.92% | -12.75% | -57.54% | -203.22% | -79.98% | -1,530.22% |
| Operating Income | -4.96M | -12.68M | -5.00M | -4.83M | -8.48M | -5.11M | -6.61M | -2.07M | -4.51M | -7.28M | -4.27M | -5.68M |
| Operating Income Ratio | -15.60% | -46.67% | -16.86% | -21.89% | -36.69% | -31.19% | -59.32% | -17.95% | -66.25% | -215.30% | -358.87% | -1,560.22% |
| Total Other Income/Expenses | 1.01M | -351.00K | -1.42M | -319.00K | -1.43M | -1.16M | -274.00K | -328.00K | 418.00K | 732.00K | -2.83M | -233.28K |
| Income Before Tax | -3.95M | -13.03M | -6.42M | -5.15M | -9.91M | -6.27M | -6.89M | -2.40M | -4.09M | -6.55M | -7.09M | -5.92M |
| Income Before Tax Ratio | -12.41% | -47.96% | -21.64% | -23.34% | -42.88% | -38.24% | -61.78% | -20.80% | -60.10% | -193.64% | -596.64% | -1,624.27% |
| Income Tax Expense | 251.00K | 315.00K | 43.00K | 237.00K | 422.00K | 209.00K | 169.00K | 404.00K | 98.00K | 525.00K | 28.00K | 0.00 |
| Net Income | -4.20M | -13.35M | -6.46M | -5.39M | -10.33M | -6.48M | -7.05M | -2.40M | -4.09M | -6.55M | -7.12M | -5.92M |
| Net Income Ratio | -13.20% | -49.12% | -21.79% | -24.41% | -44.71% | -39.51% | -63.29% | -20.80% | -60.10% | -193.64% | -598.99% | -1,624.27% |
| EPS | -0.13 | -0.43 | -0.21 | -0.24 | -0.50 | -0.39 | -0.48 | -0.17 | -0.28 | -0.46 | -0.55 | -0.49 |
| EPS Diluted | -0.13 | -0.43 | -0.21 | -0.24 | -0.50 | -0.39 | -0.48 | -0.17 | -0.28 | -0.46 | -0.55 | -0.49 |
| Weighted Avg Shares Out | 33.16M | 30.77M | 31.15M | 22.44M | 20.51M | 16.64M | 14.77M | 14.17M | 14.46M | 14.16M | 12.87M | 12.17M |
| Weighted Avg Shares Out (Dil) | 33.16M | 30.77M | 31.15M | 22.44M | 20.51M | 16.64M | 14.77M | 14.51M | 14.46M | 14.26M | 12.87M | 12.17M |
4 Stocks Worth Adding to Your Portfolio on Solid Net Profit Margin
Let's take a look at four top-ranked stocks - BWAY, QFIN, GLDD and GRC - with impressive net profit margins for a robust portfolio.
Brainsway (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why
Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Here's Why Brainsway Ltd. Sponsored ADR (BWAY) is a Great Momentum Stock to Buy
Does Brainsway Ltd. Sponsored ADR (BWAY) have what it takes to be a top stock pick for momentum investors?
BrainsWay Appoints Richard A. Bermudes, M.D.
Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field
The Zacks Analyst Blog Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay
Fulcrum Therapeutics, Heritage Insurance, Latham Group, Seanergy Maritime and BrainsWay are included in this Analyst Blog.
5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts
We have narrowed our search to five small-cap stocks that have strong momentum. These are FULC, HRTG, SWIM, SHIP and BWAY.
Wall Street Analysts See a 60.85% Upside in Brainsway (BWAY): Can the Stock Really Move This High?
The consensus price target hints at a 60.9% upside potential for Brainsway (BWAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside...
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?
Here is how Brainsway Ltd. Sponsored ADR (BWAY) and ChromaDex (CDXC) have performed compared to their sector so far this year.
Brainsway Ltd. Sponsored ADR (BWAY) Hit a 52 Week High, Can the Run Continue?
Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable
Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Source: https://incomestatements.info
Category: Stock Reports